Radix Puerariae lobatae (Gegen) suppresses the anticoagulation effect of warfarin: a pharmacokinetic and pharmacodynamics study
Tóm tắt
Radix Salvia miltiorrhiza (Danshen) and Radix Puerariae lobatae (Gegen) are used in Traditional Chinese Medicine to treat cardiovascular diseases. However, adverse herb-drug interactions were observed between warfarin and herbal remedies containing Danshen and Gegen. This study aims to investigate the pharmacokinetic and pharmacodynamic interactions between warfarin and the different components found in Danshen and Gegen. Sixty Sprague–Dawley rats were used to investigate the effects of warfarin (0.2 mg/kg), Danshen (240 or 480 mg/kg) and Gegen (240 or 480 mg/kg) both in isolation and combination. The rats in the warfarin and Danshen/Gegen combination groups were given an oral dose of Danshen or Gegen 2 h after being given an oral dose of warfarin. After five consecutive days of treatment, the pharmacokinetic interactions between Danshen/Gegen and warfarin were investigated by simultaneously monitoring and comparing the cytochrome P450 (CYP) activities, mRNA and protein expression levels in the livers of the rats from the different treatment groups. The pharmacodynamic interactions were evaluated by monitoring and comparing the vitamin K epoxide reductase (VKOR) activities, mRNA and protein expression levels in the livers of rats from the different groups, as well as the thrombomodulin (TM) activities, mRNA and protein in the lungs of these animals. The rat plasma soluble thrombomodulin concentrations of the different treatment groups were also evaluated. Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM. The activities and expression levels of the CYP and VKOR enzymes in the warfarin-Gegen combination groups increased by nearly 30 % (P = 0.02) compared with the warfarin-alone group, whereas those of TM decreased by almost 25 % (P = 0.02). The administration of Danshen did not lead to any changes in the activities or the expression levels of the CYP, VKOR or TM enzymes compared with those of the control group. Gegen induced several warfarin-metabolizing CYP enzymes and neutralized the effects of warfarin towards VKOR and TM.
Gegen, rather than Danshen at the same tested dosage, offsets the anticoagulant effects of warfarin by accelerating the phase I liver metabolism of warfarin, as well as increasing the activity, mRNA and protein expression of VKOR while decreasing those of TM.
Tài liệu tham khảo
Ge BK, Zhang Z, Zuo Z. Updates on the clinical evidenced herb-warfarin interactions. Evid Based Complement Alternat Med. 2014;2014:957362. doi:10.1155/2014/957362.
Ramsay NA, Kenny MW, Davies G, Patel JP. Complimentary and alternative medicine use among patients starting warfarin. Brit J Haematol. 2005;130:778–80.
Ernst E, Pittler MH, Stevinson C, White A. The desktop guide to complementary and alternative medicine. Br J Clin Pharmacol. 2002;54:454.
Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119:8s–21s.
Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73:67–74.
Guo L, Yamazoe Y. Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol Sin. 2004;25:129–36.
Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT, et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci. 2001;4:176–84.
Macan H, Uykimpang R, Alconcel M, Takasu J, Razon R, Amagase H, Niihara Y. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr. 2006;136:793–5.
Sakaguchi Y, Suga S, Oshida K, Miyamoto-kuramitsu K, Ueda K, Miyamoto Y. Anticoagulant effect of sodium dehydroacetate (DHA-S) in rats. J Appl Toxicol. 2008;28:524–9.
Thijssen HH, Soute BA, Vervoort LM, Claessens JG. Paracetamol (Acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb Haemost. 2004;92:797–802.
Weiler H, Isermann BH. Thrombomodulin. J Thromb Haemost. 2003;1:1515–24.
Ikemoto T, Hojo Y, Kondo H, Takahashi N, Hirose M, Nishimura Y, Katsuki T, Shimada K, Kario K. Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. Hear Vessel. 2012;27:344–51.
Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood. 1990;76:2024–9.
Dharmasaroja P, Dharmasaroja PA, Sobhon P. Increased plasma soluble thrombomodulin levels in cardioembolic stroke. Clin Appl Thromb Hem. 2012;18:289–93.
Shi CS, Huang HC, Wu HL, Kuo CH, Chang BI, Shiao MS, Shi GY. Salvianolic acid B modulates hemostasis properties of human umbilical vein endothelial cells. Thromb Res. 2007;119:769–75.
Fong CC, Wei F, Chen Y, Yu WK, Koon CM, Leung PC, Fung KP, Lau BS, Yang MS. Danshen-Gegen decoction exerts proliferative effect on rat cardiac myoblasts H9c2 via MAPK and insulin pathways. J Ethnopharmacol. 2011;138:60–6.
Chiu PY, Wong SM, Leung HY, Leong PK, Chen N, Zhou LM, Zuo Z, Lam PY, Ko KM. Long-term treatment with Danshen-Gegen decoction protects the myocardium against ischemia/reperfusion injury via the redox-sensitive protein kinase C-ε/mK(ATP) pathway in rats. Rejuv Res. 2011;14:173–84.
Chang Q, Sun L, Zhao RH, Chow MSS, Zuo Z. Simultaneous determination of ten active components in traditional Chinese medicinal products containing both Gegen (Pueraria lobata) and Danshen (Salvia miltiorrhiza) by high-performance liquid chromatography. Phytochem Anal. 2008;19:368–75.
Chook P, Tam WY, Chan LT, Qiao M, Cheng KF, Poon YK, Qiao M, Chan LT, Cheung SP, Cheng KF, Fung KP, Tang SL, Lau KM, Koon CM, Leung PC, Celermjer DS, Woo KS. Efficacy and safety of Danshen and Gegen as adjunctive secondary prevention therapy in coronary artery disease. South China J Cardio Vasc Dis. 2011;17:48–52.
Chook P, Tam LW, Poon PY, Qiao M, Chan LL, Cheung AS, Cheng KF, Fung KP, Tang SL, Koon CM, Leung PC, Celermjer DS, Woo KS. Danshen and Gegen as cardiovascular tonic in coronary patients: a novel strategy for secondary atherosclerosis prevention. South China J Cardio Vasc Dis. 2005;12:32.
Tam WY, Chook P, Qiao M, Chan LT, Chan TYK, Poon YK, Fung KP, Leung PC, Woo KS. The efficacy and tolerability of adjunctive alternative herbal medicine (Salvia miltiorrhiza and Pueraria lobata) on vascular function and structure in coronary patients. J Altern Complem Med. 2009;15:415–21.
Zhang Z, Ge BK, Zhou LM, Lam TN, Zuo Z. Induction of liver cytochrome P450 s by Danshen-Gegen formula is the leading cause for its pharmacokinetic interactions with warfarin. J Ethnopharmacol. 2014;154:672–86.
Zhou LM, Wang S, Zhang Z, Lau BS, Fung KP, Leung PC, Zuo Z. Pharmacokinetic and pharmacodynamic interaction of Danshen-Gegen extract with warfarin and aspirin. J Ethnopharmacol. 2012;143:648–55.
Cheng TO. Cardiovascular effects of Danshen. Int J Cardiol. 2007;121:9–22.
Wang BQ. Salvia miltiorrhiza: chemical and pharmacological review of a medicinal plant. J Med Plants Res. 2010;4:2813–20.
Chan TYK. Interaction between warfarin and Danshen (Salvia miltiorrhiza). Ann Pharmacother. 2001;35:501–4.
Izzat MB, Yim APC, El-Zufari MH. A taste of Chinese medicine! Ann Thorac Surg. 1998;66:941–2.
Tam LS, Chan TYK, Leung WK, Critchley JAJH. Warfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil. Aust NZ J Med. 1995;25:258.
Yu C, Chan J, Sanderson J. Chinese herbs and warfarin potentiation by ‘danshen’. J Inter Med. 1997;241:337–9.
La ACT, Chan K, Yeung JHK, Woo KS. The effects of Danshen (Salvia miltiorrhiza) on pharmacokinetics and pharmacodynamics of warfarin in rats. Eur J Drug Metab Pharmacokinet. 1992;17:257–62.
Chu Y, Zhang L, Wang X, Guo J, Guo Z, Ma X. The effect of compound Danshen dripping pills, a Chinese herb medicine, on the pharmacokinetics and pharmacodynamics of warfarin in rats. J Ethnopharmacol. 2011;137:1457–61.
Zhang Z, Lam TN, Zuo Z. Radix Puerariae: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 2013;53:787–811.
Guerra MC, Speroni E, Broccoli M, Cangini M, Pasini P, Minghett A, Crespi-Perellino N, Mirasoli M, Cantelli-Forti G, Paolini M. Comparison between Chinese medical herb Pueraria Lobata crude extract and its main isoflavone puerarin antioxidant properties and effects on rat liver CYP-catalysed drug metabolism. Life Sci. 2000;67:2997–3006.
Zheng J, Chen B, Jiang B, Zeng L, Tang ZR, Fan L, Zhou HH. The effects of puerarin on CYP2D6 and CYP1A2 activities in vivo. Arch Pharm Res. 2010;33:243–6.
Tsai HH, Lin HW, Lu YH, Chen YL, Mahady GB. A review of potential harmful interactions between anticoagulant/antiplatelet agents and Chinese herbal medicines. PLoS ONE. 2013;8:e64255.
Chinese-Pharmacopoeia, 2010. Pharmacopoeia of the People’s Republic of China Version 2010, vol. 1. Beijing: Chemical Industry Press; 2010.
Tishler M, Louis FF, Norman LW. Hydro, oxido and other derivatives of vitamin K1 and related compound. J Am Chem Soc. 1940;62:2866–71.
Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659–61.
Wallin R, Martin LF. Warfarin poisoning and vitamin K antagonism in rat and human liver. Design of a system in vitro that mimics the situation in vivo. Biochem J. 1987;241:389–96.
Fong YK, Li CR, Wo SK, Wang S, Zhou L, Zhang L, Lin G, Zuo Z. In vitro and in situ evaluation of herb-drug interactions during intestinal metabolism and absorption of baicalein. J Ethnopharmacol. 2012;141:742–53.
Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem. 1982;257:859–64.
Baldwin SJ, Bramhall JL, Ashby CA, Yue L, Murdock PR, Hood SR, Ayrton AD, Clarke SE. Cytochrome P450 gene induction in rats ex vivo assessed by quantitative real-time reverse transcriptase-polymerase chain reaction (Taqman). Drug Metab Dispos. 2006;34:1063–9.
Hoen PA, Bijsterbosch MK, van Berkel TJ, Vermeulen NP, Commandeur JN. Midazolam is a phenobarbital-like cytochrome p450 inducer in rats. J Pharmacol Exp Ther. 2001;299:921–7.
Rahmaniyan M, Patrick K, Bell NH. Characterization of recombinant CYP2C11: a vitamin D 25-hydroxylase and 24-hydroxylase. Am J Physiol Endocrinol Metab. 2005;288:e753–60.
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680–5.
Lasseur R, Longin-Sauvageon C, Videmann B, Billeret M, Berny P, Benoit E. Warfarin resistance in a French strain of rats. J Biochem Mol Toxicol. 2005;19:379–85.
He CJ, Kanfer A. Quantification and modulation of thrombomodulin activity in isolated rat and human glomeruli. Kidney Int. 1992;41:1170–4.
Yamashita T, Sekiguchi A, Iwasaki Y, Sagara K, Hatano S, Iinuma H, Aizawa T, Fu LT. Thrombomodulin and tissue factor pathway inhibitor in endocardium of rapidly paced rat atria. Circulation. 2003;108:2450–2.
Wong YC, Zuo Z. Brain disposition and catalepsy after intranasal delivery of Loxapine: role of metabolism in PK/PD of intranasal CNS drugs. Pharm Res. 2013;30:2368–84.
Martignoni M, Groothuis GMM, De Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006;2:875–94.
Fasco MJ, Silkworth JB, Dunbar DA, Kaminsky LS. Rat small intestinal cytochromes probed by warfarin metabolism. Mol Pharmacol. 1992;43:226–33.
Soucek P, Gut I. Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica. 1992;22:83–103.
Martin JH, Pharmacologist C, Physician G, Medicine D. Pharmacogenetics of warfarin—is testing clinically indicated ? Exp Clin Pharmacol. 2009;32:76–80.
Brantley SJ, Gufford BT, Dua R, Fediuk DJ, Graf TN, Scarlett YV, Fisher MB, Paine MF. Physiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interaction. CPT Pharmacometrics Syst Pharmacol. 2014;3:e107.
Zhang R, Sun J, Ma L, Wu X, Pan G, Hao H, Zhou F, Jiye A, Liu C, Shang LL, Ai H, Gao HY, Peng Y, Wu H, Wang GJ. Induction of cytochromes P450 1A1 and 1A2 by tanshinones in human HepG2 hepatoma cell line. Toxicol Appl Pharmacol. 2011;252:18–27.
Lee WYW, Zhou X, Or PMY, Kwan YW, Yeung JHK. Tanshinone I increases CYP1A2 protein expression and enzyme activity in primary rat hepatocytes. Phytomedicine. 2012;19:169–76.
Kuo YH, Lin YL, Don MJ, Chen RM, Ueng YF. Induction of cytochrome P450-dependent monooxygenase by extracts of the medicinal herb Salvia miltiorrhiza. J Pharm Pharmacol. 2006;58:521–7.
Wu WWP, Yeung JHK. Inhibition of warfarin hydroxylation by major tanshinones of Danshen (Salvia miltiorrhiza) in the rat in vitro and in vivo. Phytomedicine. 2010;17:219–26.
Zhou LM, Chow MSS, Zuo Z. Effect of sodium caprate on the oral absorptions of danshensu and salvianolic acid B. Int J Pharm. 2009;379:109–18.